Dr. Susan Galbraith

70% of those patients do not have PD-L1 expression.

So they're not eligible for a PD-L1 treatment.

So it's the majority of those patients.

And for the first time, we've seen an improvement in overall survival and a very clinically meaningful improvement with a five-month improvement.

So the next question is, why have we seen that in the tropium breast O2 study?

And I think the first thing that you're seeing is that we have a best-in-class ADC here.

You've got a stable linker.

That's very important.

That means that you've got less exposure to the payload in the peripheral circulation, and you're delivering a higher proportion of it more efficiently to the tumor cells that are expressing trope 2.

In triple negative breast cancer, that's the segment that has the highest expression of trope 2 receptor on the tumor cell surface.

That translated through to more than 60% overall response rate,

So that's really more than double that of the control arm of chemotherapy, which is 29%.

That led to also with good durability of response and improvement in immediate progression-free survival of five months.

So those are the most important things because these patients progress quickly.

And when they progress, many of them don't get to a second line treatment.

And the fact that that's then translated through to an overall survival is important.

And you brought up the point of the post-progression treatment.

I just want to be clear on the numbers though.

In both studies, over 70% of patients went on to a second line treatment.

So for the Ascent 03, the 80% of patients were 80% of the 70 something percent that got a second line treatment.